版本:
中国

BRIEF-Vericel receives FDA regenerative medicine advanced therapy designation for Ixmyelocel-T

May 10 Vericel Corp

* Vericel receives FDA regenerative medicine advanced therapy (RMAT) designation for Ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐